Department of Oncology, University of Cambridge, Cambridge, UK.
Wellcome-MRC Cambridge Stem Cell Institute, Jeffrey Cheah Biomedical Center, Cambridge Biomedical Campus, Cambridge, UK.
BMC Genomics. 2022 Apr 3;23(1):255. doi: 10.1186/s12864-022-08495-8.
The pro-neural transcription factor ASCL1 is a master regulator of neurogenesis and a key factor necessary for the reprogramming of permissive cell types to neurons. Endogenously, ASCL1 expression is often associated with neuroblast stem-ness. Moreover, ASCL1-mediated reprogramming of fibroblasts to differentiated neurons is commonly achieved using artificially high levels of ASCL1 protein, where ASCL1 acts as an "on-target" pioneer factor. However, the genome-wide effects of enhancing ASCL1 activity in a permissive neurogenic environment has not been thoroughly investigated. Here, we overexpressed ASCL1 in the neuronally-permissive context of neuroblastoma (NB) cells where modest endogenous ASCL1 supports the neuroblast programme.
Increasing ASCL1 in neuroblastoma cells both enhances binding at existing ASCL1 sites and also leads to creation of numerous additional, lower affinity binding sites. These extensive genome-wide changes in ASCL1 binding result in significant reprogramming of the NB transcriptome, redirecting it from a proliferative neuroblastic state towards one favouring neuronal differentiation. Mechanistically, ASCL1-mediated cell cycle exit and differentiation can be increased further by preventing its multi-site phosphorylation, which is associated with additional changes in genome-wide binding and gene activation profiles.
Our findings show that enhancing ASCL1 activity in a neurogenic environment both increases binding at endogenous ASCL1 sites and also results in additional binding to new low affinity sites that favours neuronal differentiation over the proliferating neuroblast programme supported by the endogenous protein. These findings have important implications for controlling processes of neurogenesis in cancer and cellular reprogramming.
神经营养转录因子 ASCL1 是神经发生的主要调节因子,也是将允许的细胞类型重编程为神经元的关键因素。内源性地,ASCL1 表达通常与神经母干细胞特性相关。此外,ASCL1 介导的成纤维细胞向分化神经元的重编程通常使用人为的高 ASCL1 蛋白水平来实现,其中 ASCL1 作为一种“靶向”先驱因子发挥作用。然而,在允许的神经发生环境中增强 ASCL1 活性的全基因组效应尚未得到彻底研究。在这里,我们在神经母细胞瘤(NB)细胞的神经允许环境中过表达 ASCL1,适度的内源性 ASCL1 支持神经母细胞程序。
在 NB 细胞中增加 ASCL1,既增强了现有 ASCL1 结合位点的结合,也导致了许多额外的、亲和力较低的结合位点的产生。ASCL1 结合的这种广泛的全基因组变化导致 NB 转录组的显著重编程,将其从增殖性神经母细胞状态重新定向为有利于神经元分化的状态。从机制上讲,通过阻止其多部位磷酸化,可以进一步增加 ASCL1 介导的细胞周期退出和分化,这与全基因组结合和基因激活谱的额外变化相关。
我们的发现表明,在神经发生环境中增强 ASCL1 活性,既增加了内源性 ASCL1 结合位点的结合,又导致了新的低亲和力结合位点的结合,有利于神经元分化,而不是由内源性蛋白支持的增殖性神经母细胞程序。这些发现对控制癌症和细胞重编程中的神经发生过程具有重要意义。